Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Reported trial records — page 27

644 records with the status reported.

Showing 0 records on this page

Records

644 documents · page 27 of 27

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
GNRH-PULSATILE-HH-PKprogramme recordGonadorelinPhase 1ReportedPhase 1 ascending doseVery low
SERM-DIAGNOSTIC-DDIprogramme recordSermorelinPhase 1ReportedRandomised crossoverVery low
EPI-RU-ELDERLY-RENAL-IMPprogramme recordEpithalonPhase 1ReportedPhase 1 ascending doseVery low
BPC-PH2-UC-BODY-COMPprogramme recordBPC-157Phase 2ReportedRandomised, double-blind, placebo-controlledVery low
THYMALIN-RU-1-OLEprogramme recordThymalinReportedSingle-arm open-labelVery low
SEMAX-RU-STROKE-ELDERLYprogramme recordSemaxReportedRandomised, double-blind, placebo-controlledVery low
GNRH-DIAGNOSTIC-BODY-COMPprogramme recordGonadorelinReportedRandomised, double-blind, placebo-controlledVery low
GNRH-PULSATILE-HH-RENAL-IMPprogramme recordGonadorelinPhase 1ReportedPhase 1 ascending doseVery low
BPC-PH2-UC-QOLprogramme recordBPC-157Phase 2ReportedRandomised, double-blind, placebo-controlledVery low
THYMALIN-RU-1-ADHERENCEprogramme recordThymalinReportedObservationalVery low
SEMAX-RU-COGNITIVE-REGIONAL-JPprogramme recordSemaxPhase 3ReportedRandomised, double-blind, placebo-controlledVery low
SELANK-RU-ANXIETY-RENAL-IMPprogramme recordSelankPhase 1ReportedPhase 1 ascending doseVery low
DSIP-HIST-SLEEP-QOLprogramme recordDSIPReportedRandomised, double-blind, placebo-controlledVery low
GNRH-DIAGNOSTIC-QOLprogramme recordGonadorelinReportedRandomised, double-blind, placebo-controlledVery low
GNRH-PULSATILE-HH-HEPATIC-IMPprogramme recordGonadorelinPhase 1ReportedPhase 1 ascending doseVery low
SERM-DIAGNOSTIC-RENAL-IMPprogramme recordSermorelinPhase 1ReportedPhase 1 ascending doseVery low
BPC-PH2-UC-REGIONAL-CNprogramme recordBPC-157Phase 3ReportedRandomised, double-blind, placebo-controlledVery low
SEMAX-RU-COGNITIVE-BODY-COMPprogramme recordSemaxReportedRandomised, double-blind, placebo-controlledVery low
GNRH-PULSATILE-HH-DDIprogramme recordGonadorelinPhase 1ReportedRandomised crossoverVery low
EPI-RU-ELDERLY-BODY-COMPprogramme recordEpithalonReportedRandomised, double-blind, placebo-controlledVery low

page 27 of 27

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.